Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K39/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/181837METHOD FOR RESCUING INFLUENZA VIRUS AND COMPOSITION THEREFOR
WO 17.09.2020
Int.Class C12N 7/01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
Appl.No PCT/CN2019/121905 Applicant ZHEJIANG SENWEI BIOPHARMACEUTICAL DEVELOPMENT CO., LTD. Inventor DAI, Dongsheng
Provided are a new method for rescuing an influenza virus and a composition therefor. The method comprises providing a host cell stably integrated with and expressing influenza virus PA, PB1, PB2 and NP genes, and introducing an influenza virus rescue system in which a stop codon is introduced into the PA, PB1, PB2 and NP genes respectively into the host cell to achieve virus rescue. The produced virus particles can be used as a live attenuated influenza vaccine, which is characterized in that, since the genes encoding the related proteins are mutated, it has no replication and proliferation ability in human and normal animal cells, and replication and proliferation can be achieved only in the host cells constructed above and it can fully stimulate the body immunity and effectively protect the body while ensuring the safety.
2.WO/2020/182197LIQUID COMPOSITION COMPRISING ANTIBODY OF HUMAN INTERLEUKIN-4 RECEPTOR ALPHA
WO 17.09.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/CN2020/079120 Applicant SUZHOU CONNECT BIOPHARMACEUTICALS, LTD. Inventor ZHENG, Wei
The present invention provides a liquid composition comprising an antibody of human interleukin-4 receptor alpha. The liquid composition comprises the antibody at a concentration of 50-200 mg/ml; and a buffer, a protectant, and a surfactant as adjuvants. The liquid composition has a pH of 5.4-6.4.
3.WO/2020/183147IMMUNOTHERAPY COMBINED WITH AN ANTI-CD38 ANTIBODY
WO 17.09.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/GB2020/050567 Applicant AUTOLUS LIMITED Inventor PEDDAREDDIGARI, Vijay
The present invention relates to the use of an anti-CD38 antibody in a subject undergoing immunotherapy wherein the anti-CD38 antibody is administered before and/or after immunotherapy.
4.WO/2020/185677BIO-RESPONSIVE ANTIBODY COMPLEXES FOR ENHANCED IMMUNOTHERAPY
WO 17.09.2020
Int.Class A61K 31/7068
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7068having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
Appl.No PCT/US2020/021709 Applicant NORTH CAROLINA STATE UNIVERSITY Inventor GU, Zhen
Disclosed are bioresponsive protein complexes comprising immune checkpoint blockade inhibitors and methods of their use.
5.WO/2020/185867IMPROVED PROCESS FOR INTEGRATION OF DNA CONSTRUCTS USING RNA-GUIDED ENDONUCLEASES
WO 17.09.2020
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
Appl.No PCT/US2020/022056 Applicant SORRENTO THERAPEUTICS, INC. Inventor DING, Beibei
There is disclosed an improved, safer and commercially efficient process for developing genetically engineered cells. More specifically, there is disclosed a process comprises introducing a donor DNA construct, a guide RNA, and an RNA-guided nuclease with the host cells to be transfected; and introducing the three components into the host cell. There is further disclosed a donor DNA construct designed for inserting a CAR (chimeric antigen receptor) into a defined genomic site of a host cell. Further, the present disclosure provides a host cell transfected with a CAR that lacks viral vectors that can present a safety concern. The disclosure provides for more efficient and more cost-effective process for engineering T cells to express CAR constructs.
6.WO/2020/185917SODIUM FLUORESCEIN AS A REVERSAL AGENT FOR AN ANTI-FLUORESCEIN CAR T CELLS AND FLUORESCEIN-PHOSPHOLIPID-ETHERS OR PROFLUORESCEIN-PHOSPHOLIPID-ETHERS
WO 17.09.2020
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/US2020/022130 Applicant SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE) Inventor JENSON, Michael C.
Some embodiments of the methods and compositions provided herein relate to modulating signaling of anti-hapten CAR T cells, such as anti-fluorescein CAR T cells, by the use or administration of an unconjugated hapten, such as unconjugated fluorescein or a salt or derivative thereof.
7.WO/2020/181376TSG-6 ANTIBODIES AND USES THEREFOR
WO 17.09.2020
Int.Class C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
Appl.No PCT/CA2020/050321 Applicant UNIVERSITY HEALTH NETWORK Inventor BROKX, Richard
The invention provides novel anti-TSG-6 antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.
8.WO/2020/181846CYSTEINE-CONTAINING ANTIBODY, DRUG CONJUGATE AND USE THEREOF
WO 17.09.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2019/123219 Applicant XDCEXPLORER (SHANGHAI) CO., LTD. Inventor XIE, Zhenhui
Provided are a cysteine-containing antibody, a drug conjugate and a use thereof. The heavy chain constant region of the antibody is a humanized γ1 chain, and the light chain constant region thereof is a humanized κ chain, wherein amino acid residues at an A site of the heavy chain constant region and/or at a B site of the light chain constant region are replaced with cysteine, so as to provide an active site for site-directed coupling with drugs.
9.WO/2020/182596DOSAGE FORM COMPRISING A POLYMERIC MATRIX
WO 17.09.2020
Int.Class A61K 9/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
Appl.No PCT/EP2020/055810 Applicant EVONIK OPERATIONS GMBH Inventor MOERS, Christian
The invention is concerned with a dosage form, comprising a polymeric matrix, comprising one or more polymer(s) and a biologically active ingredient, wherein the polymeric matrix comprises 10 % by weight or more of the one or more polymer(s) and wherein the one or more polymer(s) are polymerized from a monomer mixture comprising the monomers (a) 70 to 95 % by weight of 2-ethylhexyl methacrylate (EHMA) and ethyl methacrylate (EMA) or 2-ethylhexyl methacrylate (EHMA) and methyl methacrylate (MMA), (b) 0 to 25 % by weight of a C2 to C6 hydroxy-alkylester of acrylic acid or methacrylic acid, (c) 2.5 to 20 % by weight of a C2 to C8 alkyl ester of acrylic acid or of methacrylic acid with a quaternary cationic group in the alkyl group.
10.WO/2020/182635CARBOCYCLIC DERIVATIVES AND CONJUGATED DERIVATIVES THEREOF, AND THEIR USE IN VACCINES
WO 17.09.2020
Int.Class A61K 47/64
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Appl.No PCT/EP2020/055950 Applicant GLAXOSMITHKLINE BIOLOGICALS SA Inventor ADAMO, Roberto
The invention is in the field of vaccines and relates to oligomers having a selected degree of polymerization, obtained by connecting together a number of carbocyclic repeating units, and to conjugated derivatives thereof. The oligomers and conjugated derivatives thereof of the invention also have a selected degree of acetylation. The derivatives of the invention are useful for the preparation of immunogenic compositions, e.g. in the form of a vaccine.